Skip to main content
. 2014 Jul 15;23(24):6470–6480. doi: 10.1093/hmg/ddu367

Figure 4.

Figure 4.

Grp94 inhibitors reduce mutant myocilin levels and toxicity in HTM cells. (A) Immunofluorescence imaging of human trabecular meshwork (HTM) cells transduced with RFP-tagged lentivirus expressing RFP control, RFP-tagged WT myocilin or RFP-tagged Y437H myocilin and treated with 30 µm BnIm 01, 4-Br-BnIm or equivalent volume of DMSO vehicle. Myocilin is shown in red and the nuclear marker DAPI shown in blue (×40 magnification). (B) Quantification of immunofluorescence images detecting RFP density ± standard deviation (n = 3). Significance was measured using Student's t-test; *P < 0.05, **P < 0.01. (C) MTS assay of HTM cells overexpressing WT or Y437H myocilin following treatment with 30 µm BnIm 01, 4-Br-BnIm or vehicle equivalent (DMSO) for 6 h. Cell viability is shown prior to treatment (Pre-Tx) and following treatment (Post-Tx) ± standard deviation (n = 3). Significance was measured using the Student's t-test; *P < 0.05, **P < 0.01.